Endoscopic molecular imaging of human bladder cancer using a CD47 antibody

Ying Pan, Jens Peter Volkmer, Kathleen E. Mach, Robert V. Rouse, Jen-Jane Liu, Debashis Sahoo, Timothy C. Chang, Thomas J. Metzner, Lei Kang, Matt Van De Rijn, Eila C. Skinner, Sanjiv S. Gambhir, Irving L. Weissman, Joseph C. Liao

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

A combination of optical imaging technologies with cancer-specific molecular imaging agents is a potentially powerful strategy to improve cancer detection and enable image-guided surgery. Bladder cancer is primarily managed endoscopically by white light cystoscopy with suboptimal diagnostic accuracy. Emerging optical imaging technologies hold great potential for improved diagnostic accuracy but lack imaging agents for molecular specificity. Using fluorescently labeled CD47 antibody (anti-CD47) as molecular imaging agent, we demonstrated consistent identification of bladder cancer with clinical grade fluorescence imaging systems, confocal endomicroscopy, and blue light cystoscopy in fresh surgically removed human bladders. With blue light cystoscopy, the sensitivity and specificity for CD47-targeted imaging were 82.9 and 90.5%, respectively. We detected variants of bladder cancers, which are diagnostic challenges, including carcinoma in situ, residual carcinoma in tumor resection bed, recurrent carcinoma following prior intravesical immunotherapy with Bacillus Calmette-Guérin (BCG), and excluded cancer from benign but suspicious-appearing mucosa. CD47-targeted molecular imaging could improve diagnosis and resection thoroughness for bladder cancer.

Original languageEnglish (US)
Article number260ra148
JournalScience Translational Medicine
Volume6
Issue number260
DOIs
StatePublished - Oct 29 2014
Externally publishedYes

Fingerprint

Molecular Imaging
Urinary Bladder Neoplasms
Cystoscopy
Optical Imaging
Antibodies
Light
Neoplasms
Computer-Assisted Surgery
Technology
Carcinoma
Carcinoma in Situ
Immunotherapy
Bacillus
Anti-Idiotypic Antibodies
Mucous Membrane
Urinary Bladder
Sensitivity and Specificity

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Pan, Y., Volkmer, J. P., Mach, K. E., Rouse, R. V., Liu, J-J., Sahoo, D., ... Liao, J. C. (2014). Endoscopic molecular imaging of human bladder cancer using a CD47 antibody. Science Translational Medicine, 6(260), [260ra148]. https://doi.org/10.1126/scitranslmed.3009457

Endoscopic molecular imaging of human bladder cancer using a CD47 antibody. / Pan, Ying; Volkmer, Jens Peter; Mach, Kathleen E.; Rouse, Robert V.; Liu, Jen-Jane; Sahoo, Debashis; Chang, Timothy C.; Metzner, Thomas J.; Kang, Lei; Van De Rijn, Matt; Skinner, Eila C.; Gambhir, Sanjiv S.; Weissman, Irving L.; Liao, Joseph C.

In: Science Translational Medicine, Vol. 6, No. 260, 260ra148, 29.10.2014.

Research output: Contribution to journalArticle

Pan, Y, Volkmer, JP, Mach, KE, Rouse, RV, Liu, J-J, Sahoo, D, Chang, TC, Metzner, TJ, Kang, L, Van De Rijn, M, Skinner, EC, Gambhir, SS, Weissman, IL & Liao, JC 2014, 'Endoscopic molecular imaging of human bladder cancer using a CD47 antibody', Science Translational Medicine, vol. 6, no. 260, 260ra148. https://doi.org/10.1126/scitranslmed.3009457
Pan, Ying ; Volkmer, Jens Peter ; Mach, Kathleen E. ; Rouse, Robert V. ; Liu, Jen-Jane ; Sahoo, Debashis ; Chang, Timothy C. ; Metzner, Thomas J. ; Kang, Lei ; Van De Rijn, Matt ; Skinner, Eila C. ; Gambhir, Sanjiv S. ; Weissman, Irving L. ; Liao, Joseph C. / Endoscopic molecular imaging of human bladder cancer using a CD47 antibody. In: Science Translational Medicine. 2014 ; Vol. 6, No. 260.
@article{ba64501f99f747f88b9500fe5724d23a,
title = "Endoscopic molecular imaging of human bladder cancer using a CD47 antibody",
abstract = "A combination of optical imaging technologies with cancer-specific molecular imaging agents is a potentially powerful strategy to improve cancer detection and enable image-guided surgery. Bladder cancer is primarily managed endoscopically by white light cystoscopy with suboptimal diagnostic accuracy. Emerging optical imaging technologies hold great potential for improved diagnostic accuracy but lack imaging agents for molecular specificity. Using fluorescently labeled CD47 antibody (anti-CD47) as molecular imaging agent, we demonstrated consistent identification of bladder cancer with clinical grade fluorescence imaging systems, confocal endomicroscopy, and blue light cystoscopy in fresh surgically removed human bladders. With blue light cystoscopy, the sensitivity and specificity for CD47-targeted imaging were 82.9 and 90.5{\%}, respectively. We detected variants of bladder cancers, which are diagnostic challenges, including carcinoma in situ, residual carcinoma in tumor resection bed, recurrent carcinoma following prior intravesical immunotherapy with Bacillus Calmette-Gu{\'e}rin (BCG), and excluded cancer from benign but suspicious-appearing mucosa. CD47-targeted molecular imaging could improve diagnosis and resection thoroughness for bladder cancer.",
author = "Ying Pan and Volkmer, {Jens Peter} and Mach, {Kathleen E.} and Rouse, {Robert V.} and Jen-Jane Liu and Debashis Sahoo and Chang, {Timothy C.} and Metzner, {Thomas J.} and Lei Kang and {Van De Rijn}, Matt and Skinner, {Eila C.} and Gambhir, {Sanjiv S.} and Weissman, {Irving L.} and Liao, {Joseph C.}",
year = "2014",
month = "10",
day = "29",
doi = "10.1126/scitranslmed.3009457",
language = "English (US)",
volume = "6",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science",
number = "260",

}

TY - JOUR

T1 - Endoscopic molecular imaging of human bladder cancer using a CD47 antibody

AU - Pan, Ying

AU - Volkmer, Jens Peter

AU - Mach, Kathleen E.

AU - Rouse, Robert V.

AU - Liu, Jen-Jane

AU - Sahoo, Debashis

AU - Chang, Timothy C.

AU - Metzner, Thomas J.

AU - Kang, Lei

AU - Van De Rijn, Matt

AU - Skinner, Eila C.

AU - Gambhir, Sanjiv S.

AU - Weissman, Irving L.

AU - Liao, Joseph C.

PY - 2014/10/29

Y1 - 2014/10/29

N2 - A combination of optical imaging technologies with cancer-specific molecular imaging agents is a potentially powerful strategy to improve cancer detection and enable image-guided surgery. Bladder cancer is primarily managed endoscopically by white light cystoscopy with suboptimal diagnostic accuracy. Emerging optical imaging technologies hold great potential for improved diagnostic accuracy but lack imaging agents for molecular specificity. Using fluorescently labeled CD47 antibody (anti-CD47) as molecular imaging agent, we demonstrated consistent identification of bladder cancer with clinical grade fluorescence imaging systems, confocal endomicroscopy, and blue light cystoscopy in fresh surgically removed human bladders. With blue light cystoscopy, the sensitivity and specificity for CD47-targeted imaging were 82.9 and 90.5%, respectively. We detected variants of bladder cancers, which are diagnostic challenges, including carcinoma in situ, residual carcinoma in tumor resection bed, recurrent carcinoma following prior intravesical immunotherapy with Bacillus Calmette-Guérin (BCG), and excluded cancer from benign but suspicious-appearing mucosa. CD47-targeted molecular imaging could improve diagnosis and resection thoroughness for bladder cancer.

AB - A combination of optical imaging technologies with cancer-specific molecular imaging agents is a potentially powerful strategy to improve cancer detection and enable image-guided surgery. Bladder cancer is primarily managed endoscopically by white light cystoscopy with suboptimal diagnostic accuracy. Emerging optical imaging technologies hold great potential for improved diagnostic accuracy but lack imaging agents for molecular specificity. Using fluorescently labeled CD47 antibody (anti-CD47) as molecular imaging agent, we demonstrated consistent identification of bladder cancer with clinical grade fluorescence imaging systems, confocal endomicroscopy, and blue light cystoscopy in fresh surgically removed human bladders. With blue light cystoscopy, the sensitivity and specificity for CD47-targeted imaging were 82.9 and 90.5%, respectively. We detected variants of bladder cancers, which are diagnostic challenges, including carcinoma in situ, residual carcinoma in tumor resection bed, recurrent carcinoma following prior intravesical immunotherapy with Bacillus Calmette-Guérin (BCG), and excluded cancer from benign but suspicious-appearing mucosa. CD47-targeted molecular imaging could improve diagnosis and resection thoroughness for bladder cancer.

UR - http://www.scopus.com/inward/record.url?scp=84908568498&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908568498&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.3009457

DO - 10.1126/scitranslmed.3009457

M3 - Article

VL - 6

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 260

M1 - 260ra148

ER -